Skip to main content
. 2021 Jul 17;22(14):7658. doi: 10.3390/ijms22147658

Figure 4.

Figure 4

The IC50 of erlotinib in the dataset Genomics of Drug Sensitivity in Cancer 1 (GDSC1) had significant negative correlation with hsa-miR-142-3p. The NSCLC cell lines were divided with mean ± 0.5 standard deviation (SD) into three groups: sensitive, partial response, and resistant. The sensitive and resistant groups had significantly differential expression with a fold change (FC) = 0.45.